title: Meta-analysis of the association between progression-free survival and overall survival in metastatic colorectal cancer.
abstract: OBJECTIVE
  The validity of progression-free survival (PFS) as a surrogate endpoint for overall survival (OS) in metastatic colorectal cancer (mCRC) trials has been studied, primarily in first-line treatment. The relationship between PFS and OS has not been well studied in later lines of treatment.
  
  
  METHODS
  We conducted a systematic literature review of mCRC phase 2 and 3 clinical trials that reported OS and PFS (or time-to-progression [TTP]) data. Correlation between endpoints (either PFS alone or PFS aggregated with TTP [PFS_TTP]) was estimated within treatment arms. Treatment effect was the ratio of the median time to OS, PFS, or PFS_TTP in the "control" versus "experimental" arm. We conducted meta-regression analyses and performed receiver-operating characteristic (ROC) analysis.
  
  
  RESULTS
  We analyzed data from 62 articles (23,527 patients). A high positive correlation was found between median PFS_TTP and median OS within treatment arms (r = 0.87; 95% confidence interval [CI], 0.82-0.91) and also between the median OS and median PFS (r = 0.89, 95% CI, 0.83-0.93)]. R(2) was 0.48 for PFS_TTP and 0.59 for PFS; R (2) for PFS_TTP was higher for first-line (R(2) = 0.54) than second-line studies (R(2) = 0.38). The ROC analysis is presented as a conceptual tool for evaluating the performance of PFS as a surrogate for OS at various thresholds.
  
  
  CONCLUSIONS
  The correlation of PFS, alone or aggregated with TTP, with OS in clinical trials of patients with mCRC is robust across lines of therapy and provides a useful means of predicting improvements in OS using PFS data.
authors.affiliation: Biometrics, RTI Health Solutions, 200 Park Offices Drive, PO Box 12194, Research Triangle Park, NC 27709, USA. cchirila@rti.org
authors.forename: Costel
authors.initials: C
authors.lastname: Chirila
authors.forename: Dawn
authors.initials: D
authors.lastname: Odom
authors.forename: Giovanna
authors.initials: G
authors.lastname: Devercelli
authors.forename: Shahnaz
authors.initials: S
authors.lastname: Khan
authors.forename: Bintu N
authors.initials: BN
authors.lastname: Sherif
authors.forename: James A
authors.initials: JA
authors.lastname: Kaye
authors.forename: István
authors.initials: I
authors.lastname: Molnár
authors.forename: Beth
authors.initials: B
authors.lastname: Sherrill
mesh_terms: D015179:Colorectal Neoplasms / Q000401:mortality* / Q000473:pathology; D018572:Disease-Free Survival; D006801:Humans; D009362:Neoplasm Metastasis; D012372:ROC Curve; D016019:Survival Analysis
references.citation: Cancer. 1950 Jan;3(1):32-5
references.pmid: 15405679
references.citation: J Clin Oncol. 2004 Dec 1;22(23):4753-61
references.pmid: 15570076
references.citation: Stat Med. 1992 Jan 30;11(2):167-78
references.pmid: 1579756
references.citation: Br J Cancer. 2008 Nov 18;99(10):1572-8
references.pmid: 19002178
references.citation: Oncology. 2007;73(1-2):9-20
references.pmid: 18334829
references.citation: J Clin Oncol. 2009 Jun 10;27(17):2874-80
references.pmid: 19414672
references.citation: J Clin Oncol. 2003 Apr 1;21(7):1404-11
references.pmid: 12663734
references.citation: J Clin Oncol. 2003 Jan 1;21(1):60-5
references.pmid: 12506171
references.citation: Int J Clin Oncol. 2009 Apr;14(2):102-11
references.pmid: 19390940
references.citation: Biostatistics. 2000 Mar;1(1):49-67
references.pmid: 12933525
references.citation: J Clin Oncol. 2005 Dec 1;23(34):8664-70
references.pmid: 16260700
references.citation: Stat Med. 1989 Apr;8(4):431-40
references.pmid: 2727467
references.citation: J Thorac Oncol. 2009 Aug;4(8):994-1001
references.pmid: 19633474
references.citation: J Clin Oncol. 2007 Oct 20;25(30):4779-86
references.pmid: 17947725
references.citation: J Clin Oncol. 2009 Feb 10;27(5):672-80
references.pmid: 19114685
references.citation: J Clin Oncol. 2007 Nov 20;25(33):5218-24
references.pmid: 18024867
references.citation: Lancet. 2000 Jul 29;356(9227):373-8
references.pmid: 10972369
references.citation: Ann Oncol. 2010 Jan;21(1):7-12
references.pmid: 19901012
references.citation: J Clin Oncol. 2007 May 1;25(13):1658-64
references.pmid: 17470858
references.citation: J Clin Oncol. 2007 Oct 10;25(29):4562-8
references.pmid: 17876010
references.citation: Biometrics. 1998 Sep;54(3):1014-29
references.pmid: 9840970
references.citation: Lancet Oncol. 2006 Sep;7(9):741-6
references.pmid: 16945769
references.citation: Cancer. 2001 Jun 1;91(11):2033-8
references.pmid: 11391582